Maurice Enriquez-Sarano, MD, FACC, FAHA, FESC
Valve Science Center Minneapolis Heart Institute USA
The 71st conference will consist of a vibrant program including new medical innovations and technology updates, leading international keynote speakers, parallel and satellite sessions on the latest research in our field. This conference is a real opportunity for meaningful collaboration with colleagues from Israel and across the globe and a chance to make an impact.
For our international visitors, we will offer ample opportunity to tour our exceptional country and enjoy its heritage, unique views, and culture.
We look forward to seeing you in Tel Aviv.
Valve Science Center Minneapolis Heart Institute
Department of Cardiovascular Medicine, Cleveland Clinic
Dr. Maurice Enriquez-Sarano is a cardiologist with expertise in heart valve diseases and cardiac imaging. He got his MD degree and medical training from Sorbonne University, Paris, France. He joined the Mayo Clinic, was the founding director of the Heart Valve Clinic and Professor of Medicine at Mayo Clinic, Rochester, MN, and was a founding member and past-president of the Heart Valve Society. Dr. Sarano authored over 500 peer-reviewed publications and book chapters, with h-index 108 (Scopus) to 118 (Google) and mentored numerous trainees who became leading scholars in valve diseases. He is Senior Scientist at the Minneapolis Heart Institute and founder of ValThera (ValThera.io), a startup developing innovative transcatheter treatment for tricuspid regurgitation. He is a member of “La Chaine de L’espoir” and board member of “United Surgeons for Children”, supporting the treatment of patients affected by Valvular Heart Diseases in low-resources countries.
Dr. Lincoff is Vice Chair for Research and an interventional cardiologist in the Department of Cardiovascular Medicine at the Cleveland Clinic. He is a Professor of Medicine at the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University and holds the Charles and Charlotte Fowler Endowed Chair for Cardiovascular Research. His research activities focus on development of metabolic or antithrombotic therapies to prevent or reduce progression of atherosclerosis or optimize management of acute coronary syndromes or percutaneous coronary intervention. He has served as principal investigator or steering committee member for over 50 trials in ischemic and cardiometabolic diseases.